Proteinuria with and without renal glomerular podocyte effacement

被引:60
作者
Kalluri, Raghu
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Matrix Biol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[3] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 09期
关键词
D O I
10.1681/ASN.2006060628
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Renal biopsies of patients with proteinuria and kidney disease most often are associated with podocyte foot process effacement. For several decades, nephrologists have wondered whether proteinuria is a result of podocyte foot process effacement or the cause of it. In the past few years, the author's laboratory has addressed this issue using different mouse models of proteinuria. Although in most cases, podocyte effacement is associated with proteinuria and glomerular disease, in three different mouse models, it was demonstrated that proteinuria can be observed without podocyte foot process effacement. The first model is generated by injection of antibodies to vascular endothelial growth factor or soluble vascular endothelial growth factor receptor 1. The second model is a mouse with deletion of type IV collagen alpha 3 chain in the glomerular basement membrane. The third model was generated by genetic deletion of a slit diaphragm protein known as nephrin. Collectively, these experiments and the supporting evidence from several human studies demonstrate that severe defects in either the glomerular basement membrane or the glomerular endothelium can lead to proteinuria without foot process effacement.
引用
收藏
页码:2383 / 2389
页数:7
相关论文
共 49 条
[1]   Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis [J].
Branten, AJW ;
van den Born, J ;
Jansen, JLJ ;
Assmann, KJM ;
Wetzels, JFM ;
Dijkman, HBPM .
KIDNEY INTERNATIONAL, 2001, 59 (02) :693-701
[2]  
Brenner BM, 2004, J AM SOC NEPHROL, V15, P1354
[3]   Retarding the progression of renal disease [J].
Brenner, BM .
KIDNEY INTERNATIONAL, 2003, 64 (01) :370-378
[4]   A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation [J].
Clark, DE ;
Smith, SK ;
He, YL ;
Day, KA ;
Licence, DR ;
Corps, AN ;
Lammoglia, R ;
Charnock-Jones, DS .
BIOLOGY OF REPRODUCTION, 1998, 59 (06) :1540-1548
[5]   Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome [J].
Cosgrove, D ;
Meehan, DT ;
Grunkemeyer, JA ;
Kornak, JM ;
Sayers, R ;
Hunter, WJ ;
Samuelson, GC .
GENES & DEVELOPMENT, 1996, 10 (23) :2981-2992
[6]  
COUSER WG, 1991, SEMIN NEPHROL, V11, P254
[7]   Discovery of vascular permeability factor (VPF) [J].
Dvorak, HF .
EXPERIMENTAL CELL RESEARCH, 2006, 312 (05) :522-526
[8]  
FARQUHAR M G, 1957, Schweiz Med Wochenschr, V87, P501
[9]   AN ELECTRON MICROSCOPE STUDY OF THE GLOMERULUS IN NEPHROSIS, GLOMERULONEPHRITIS, AND LUPUS ERYTHEMATOSUS [J].
FARQUHAR, MG ;
VERNIER, RL ;
GOOD, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1957, 106 (05) :649-&
[10]   PRIMARY GLOMERULAR-FILTRATION BARRIER - BASEMENT-MEMBRANE OR EPITHELIAL SLITS [J].
FARQUHAR, MG .
KIDNEY INTERNATIONAL, 1975, 8 (04) :197-211